Current status of bevacizumab in advanced ovarian cancer

Overview of attention for article published in OncoTargets and therapy, July 2013

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 22 Mendeley
citeulike: 1 CiteULike

Summary X Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

AADAC promotes therapeutic activity of cisplatin and imatinib against ovarian cancer cells.

Article in Cellular and molecular biology (April 2022)

Chapter 15 Application of cancer stem cells in improving therapeutics

Book chapter (January 2021)

The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review

Article in Biomedicine & Pharmacotherapy (April 2018)